Construction of Epitope-Based Peptide Vaccine Against SARS-CoV-2: Immunoinformatics Study
Recently, a novel coronavirus (SARS-CoV-2) appeared which is conscientious for the current outbreak in China and rapidly spread worldwide. Unluckily, there is no approved vaccine found against SARSCoV-2. Therefore, there is an urgent need for designing a suitable peptide vaccine constituent against...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Journal of Pure and Applied Microbiology
2020-05-01
|
Series: | Journal of Pure and Applied Microbiology |
Subjects: | |
Online Access: | https://microbiologyjournal.org/construction-of-epitope-based-peptide-vaccine-against-sars-cov-2-immunoinformatics-study/ |
Summary: | Recently, a novel coronavirus (SARS-CoV-2) appeared which is conscientious for the current outbreak
in China and rapidly spread worldwide. Unluckily, there is no approved vaccine found against SARSCoV-2. Therefore, there is an urgent need for designing a suitable peptide vaccine constituent against
the SARS-CoV-2. In this study, we characterized the spike glycoprotein of SARS-CoV-2 to obtain
immunogenic epitopes. In addition, we used 58 SARS-CoV-2 isolates were retrieved from the Global
Initiative on Sharing All Influenza Data (GISAID) and National Center for Biotechnology Information
(NCBI), then aligned to obtain the conserved region of SARS-CoV-2 spike glycoprotein. The interaction
between the conserved region with ACE2 receptor, a SARS-CoV-2 receptor on the host cell, has been
evaluated through molecular docking approach. The B-cell epitope was identified using the immune
epitope database (IEDB) web server. Interestingly, we recommend Pep_4 ADHQPQTFVNTELH as a
epitope-based peptide vaccine candidate to deal with the SARS-CoV-2 outbreak. Pep_4 has a high level
of immunogenicity and does not trigger autoimmune mechanisms. Pep_4 is capable of forming BCR/
Fab molecular complexes with the lowest binding energy for activation of transduction signal the direct
B-cell immune response. However, further study is suggested for confirmation (in vitro and in vivo). |
---|---|
ISSN: | 0973-7510 2581-690X |